Frequency of coexistent disease at CT in patients with prostate carcinoma selected for definitive radiation therapy: Is limited treatment- planning CT adequate?

Radiology

Volumn 215, Issue 1, 2000, Pages 41-44

  Miller, Jeffrey S ^a   Puckett, Michael L ^a   Johnstone, Peter A S ^a,b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abdomen, CT; Computed tomography (CT), contrast enhancement; Computed tomography (CT), treatment planning; Cost effectiveness; Prostate neoplasms, CT

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CARDIOMEGALY; COMORBIDITY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HEPATOBILIARY DISEASE; HERNIA; HUMAN; INCIDENCE; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS DISEASE; PRIORITY JOURNAL; PROSTATE CARCINOMA;

EID: 0034084952     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.215.1.r00ap4241     Document Type: Article

References (13)

1. Leibel SA, Zelefsky MJ, Kutcher GJ, et al. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994; 21:580-597.
2. Huncharek M, Muscat J. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. Cancer Invest 1995; 13:31-35.
3. Huncharek M, Muscat J. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer. Abdom Imaging 1996; 21:364-367.
4. Levran Z, Gonzalez JA, Kiokno AC, Jafri SZ, Steinert BW. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostate cancer? Br J Urol 1995; 75:778-781.
5. Perez CA. Carcinoma of the prostate: a model for management under impending health care system reform - 1994 RSNA annual oration in radiation oncology. Radiology 1995; 196:309-322.
6. Forman HF, Heiken JP, Brink JA, Glazer HS, Fox LA, McClennan. CT screening for comorbid disease in patients with prostatic carcinoma: is it cost effective? AJR Am J Roentgenol 1994; 162:1125-1128.
7. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47:5-27.
8. Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer 1998; 83:1180-1188.
9. Powell CR, Huisman TK, Riffenburgh RH, Saunders EL. Bethel KJ, Johnstone PA. Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy. J Urol 1997; 157:1754-1759.
10. Johnstone PA, Tarman GJ, Riffenburgh R, Rohde DC, Puckett ML, Kane CJ. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol Oncol 1997; 3:108-112.
11. Monfardini S, Fratino L, Audisio R, Gioia F, Dal Lago D, Zagonel V. Less co-morbidity in elderly cancer patients undergoing chemotherapy or radiotherapy (abstr). Proc Ann Meet Am Soc Clin Oncol 1997; 16:A267.
12. Repetto L, Venturino A, Vercelli M, et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 1998; 82:760-765.
13. Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff RM. Patterns of care related to age of men with prostate cancer. Cancer 1991; 67:2633-2641.